摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[2-pyridyl-(methyl)methylsulfinyl]-(5-ethyl)benzimidazole | 60524-94-9

中文名称
——
中文别名
——
英文名称
2-[2-pyridyl-(methyl)methylsulfinyl]-(5-ethyl)benzimidazole
英文别名
6-ethyl-2-(1-pyridin-2-ylethylsulfinyl)-1H-benzimidazole
2-[2-pyridyl-(methyl)methylsulfinyl]-(5-ethyl)benzimidazole化学式
CAS
60524-94-9
化学式
C16H17N3OS
mdl
——
分子量
299.396
InChiKey
GIJDLNVCIPUWFT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    540.0±52.0 °C(Predicted)
  • 密度:
    1.32±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    77.8
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Benzimidazoles and their pharmaceutical use
    申请人:THE UPJOHN COMPANY
    公开号:EP0045200A1
    公开(公告)日:1982-02-03
    Substituted alkylsulfinylbenzimidazoles for use as pharmaceuticals or as active ingredients in pharmaceutical compositions, especially of the formula wherein R1, R2, R3 and -X1-Het are defined as given in the description. The compounds are used in the treatment or prevention of special gastrointestinal inflammatory diseases.
    用作药物或药物组合物活性成分的取代烷基亚磺酰基苯并咪唑,特别是以下式子 其中 R1、R2、R3 和 -X1-Het 的定义如描述中所给。这些化合物可用于治疗或预防特殊的胃肠道炎症疾病。
  • COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS
    申请人:Atopix Therapeutics Limited
    公开号:EP2790696A1
    公开(公告)日:2014-10-22
  • Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
    申请人:Atopix Therapeutics Limited
    公开号:US20140328861A1
    公开(公告)日:2014-11-06
    Disclosed are methods and compositions for preventing, treating, or ameliorating eosinophilic esophagitis (EoE) in an individual, comprising administering to the individual a therapeutically effective amount of at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor (PPI) or a pharmaceutically acceptable salt thereof. Also disclosed are compositions comprising at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor or a pharmaceutically acceptable salt thereof.
  • US4045563A
    申请人:——
    公开号:US4045563A
    公开(公告)日:1977-08-30
  • US4359465A
    申请人:——
    公开号:US4359465A
    公开(公告)日:1982-11-16
查看更多